TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens

被引:33
作者
Jones, Ronald N. [1 ]
Moet, Gary J. [1 ]
Sader, Helio S. [1 ]
Mendes, Rodrigo E. [1 ]
Castanheira, Mariana [1 ]
机构
[1] JMI Labs, N Liberty, IA 52317 USA
关键词
oxazolidinones; cfr; mutation studies; TR-701; UNITED-STATES; OXAZOLIDINONE;
D O I
10.1093/jac/dkp021
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
TR-700, the active component of the oxazolidinone prodrug TR-701, has demonstrated potent activity against numerous Gram-positive species. In this study, single-step mutation frequencies, passaging and the activity of TR-700 were tested against a worldwide collection of linezolid-non-susceptible organisms and matched controls. One hundred and twenty linezolid-non-susceptible and 120 controls matched by genus/species, geographic origin, site of infection and time were susceptibility tested by reference broth microdilution methods. Species of isolates were: Enterococcus faecalis (16 linezolid non-susceptible/16 wild-type strains); Enterococcus faecium (55/55), Staphylococcus aureus (8/8); coagulase-negative staphylococci (at least 7 spp., 40/40) and viridans group streptococci (2 spp., 1/1). 23S rRNA target mutations or cfr genes were detected by PCR and sequencing. Among linezolid-non-susceptible strains, the resistance mechanisms were G2576T (109), cfr (4) and unknown (7), with strains originating from Europe, Far East and North and South America. Most strains were multidrug-resistant and cfr isolates exhibited co-resistance to phenicols, clindamycin, linezolid, pleuromutilins and streptogramin B. TR-700 MIC values, regardless of species, were 4-32-fold lower than those of linezolid. TR-700 MIC results were <= 4, <= 8 or <= 16 mg/L for 88%, 96% and > 99% of linezolid-non-susceptible strains, respectively. Spontaneous single-step mutations were undetected (< 1.1x10(-9)) and 14 day passaging studies produced modest TR-700 MIC elevations compared with linezolid controls. TR-700 exhibited enhanced activity against linezolid-non-susceptible and wild-type control strains of Gram-positive cocci. A significant number (nearly 90%) of linezolid-non-susceptible strains were inhibited by potentially achievable levels (<= 4 mg/L) of TR-700. All strains with the emerging cfr-mediated resistance determinant had TR-700 MIC results at <= 8 mg/L.
引用
收藏
页码:716 / 720
页数:5
相关论文
共 8 条
[1]  
[Anonymous], 2012, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard
[2]  
[Anonymous], M100S18 CLSI S
[3]   Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats [J].
Bae, Soo K. ;
Yang, Si H. ;
Shin, Karen N. ;
Rhee, Jae K. ;
Yoo, Moohi ;
Lee, Myung G. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (07) :955-963
[4]   Oxazolidinone antibiotics [J].
Diekema, DJ ;
Jones, RN .
LANCET, 2001, 358 (9297) :1975-1982
[5]  
IM W, 2007, 47 INT C ANT AG CHEM, P249
[6]   United States resistance surveillance results for linezolid (LEADER Program for 2007) [J].
Jones, Ronald N. ;
Ross, James E. ;
Castanheira, Mariana ;
Mendes, Rodrigo E. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 62 (04) :416-426
[7]   Antimicrobial resistance to linezolid [J].
Meka, VG ;
Gold, HS .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :1010-1015
[8]   First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States [J].
Mendes, Rodrigo E. ;
Deshpande, Lalitagauri M. ;
Castanheira, Mariana ;
DiPersio, Joseph ;
Saubolle, Michael A. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) :2244-2246